Literature DB >> 1332596

Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model.

K Vance-Bryan1, T A Larson, J C Rotschafer, J P Toscano.   

Abstract

The purpose of this study was to develop a pharmacodynamic model to describe the dependency of the rate of Staphylococcus aureus killing upon the concentration of daptomycin. A range of free (unbound) daptomycin concentrations ranging from 0.12 to 27 times the MIC were simulated in the peripheral compartment of a two-compartment pharmacokinetic model. Log-linear regression of free daptomycin concentrations versus growth or kill rate constants showed a significant correlation (r = -0.90; P less than 0.001). A Lineweaver-Burk plot of the reciprocal transformation of these data yielded a poor fit (r = -0.38; P greater than 0.05). When a Lineweaver-Burk-type regression analysis was performed on the reciprocal of the change in the rate constant rather than the rate constant itself, the result demonstrated good correlation (r = 0.90; P less than 0.0001). The observations were also well described by a sigmoidal maximum plateau pharmacologic effect model, in which the pharmacologic effect of daptomycin is a reduction in the bacterial exponential growth rate constant from the baseline in the absence of antibiotic to a lower (positive) growth or (negative) death rate constant observed in the presence of antibiotic. These data confirm that daptomycin exhibits concentration-dependent killing over a wide range of free daptomycin concentrations relative to the MIC and suggest that this is a saturable process similar to the Michaelis-Menten pharmacokinetic elimination of certain drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1332596      PMCID: PMC245499          DOI: 10.1128/AAC.36.10.2334

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies.

Authors:  C W Stratton; C Liu; H B Ratner; L S Weeks
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

2.  Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

3.  In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

4.  In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; S Willey; E Reiszner; P G Spitzer; G Caputo; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

5.  In vitro activity of LY146032 (daptomycin), a new peptolide.

Authors:  F Ehlert; H C Neu
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

6.  In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.

Authors:  J H Jorgensen; L A Maher; J S Redding
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

7.  Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies.

Authors:  C W Stratton; L S Weeks
Journal:  Diagn Microbiol Infect Dis       Date:  1990 May-Jun       Impact factor: 2.803

8.  Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin.

Authors:  P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

9.  Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus.

Authors:  J P Flandrois; G Fardel; G Carret
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

10.  Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model.

Authors:  M W Garrison; K Vance-Bryan; T A Larson; J P Toscano; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

View more
  6 in total

Review 1.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

2.  Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.

Authors:  Joseph S Bubalo; Myrna Y Munar; Ganesh Cherala; Brandon Hayes-Lattin; Richard Maziarz
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

Review 3.  Daptomycin.

Authors:  Caroline Fenton; Gillian M Keating; Monique P Curran
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.

Authors:  Barry H Dvorchik; David Brazier; Michael F DeBruin; Robert D Arbeit
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

5.  Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.

Authors:  Sandrine Lemaire; Françoise Van Bambeke; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2007-06-04       Impact factor: 5.191

Review 6.  Daptomycin: a cyclic lipopeptide antimicrobial agent.

Authors:  LilyAnn Jeu; Horatio B Fung
Journal:  Clin Ther       Date:  2004-11       Impact factor: 3.393

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.